ClinicalTrials.gg
RecruitingNCT06919484Updated Nov 26, 2025

The Physiological Effect of RCexp on Ventilation/Perfusion Distribution

An observational study in Acute Respiratory Distress Syndrome and Mechanical Ventilation, sponsored by Southeast University, China. Recruiting at 1 site in China. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Southeast University, China · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
60
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Respiratory Distress Syndrome by Southeast University, China — 10 open to participants now, 10 under way, 2 of them phase 3. Respiratory Distress Syndrome · Southeast University, China.

Planned enrollment
8th of 13
60 · median 134
Started
2025
with 1 other
Observational
13 of 24
5 open now
Registered
18th of 24
by date

Among the 24 studies in Respiratory Distress Syndrome by Southeast University, China, this one is the 8th largest by planned enrollment of the 13 observational ones that give a count, is one of 2 that started in 2025, is one of 13 observational ones, and was the 18th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

10 of the 24 studies in Respiratory Distress Syndrome by Southeast University, China are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Respiratory Distress Syndrome by Southeast University, China, or all of them as a file.
02

Study summary

With the exception of setting the positive end-expiratory pressure (PEEP), the expiratory phase is commonly overlooked during MV. The expiratory time constant (RCexp) plays an important role in understanding the mechanical properties of the respiratory system in patients receiving mechanical ventilation. However, it is unclear that the effect of expiratory time constant on the ventilation and perfusion distribution.

Read the detailed description

With the exception of setting the positive end-expiratory pressure (PEEP), the expiratory phase is commonly overlooked during MV. The expiratory time constant (RCexp) plays an important role in understanding the mechanical properties of the respiratory system in patients receiving mechanical ventilation. However, it is unclear that the effect of expiratory time constant on the ventilation and perfusion distribution.

03

Conditions studied

  • Acute Respiratory Distress Syndrome
  • Mechanical Ventilation
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

  1. Intubated patients with moderate and severe ARDS (Berlin definition, PaO2/FiO2 ≤200 mmHg at PEEP 5 cmH2O)
  2. undergoing deep sedation on controlled mechanical ventilation within72 hours after ARDS onset

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

adult patients with ARDS receiving mechanical ventilation no more than 72 hours

Exclusion criteria

Exclusion Criteria:

  1. age \<18 years old
  2. patient undergoing legal protection
  3. to EIT (e. g. severe chest trauma or wounds)
  4. pneumothorax
  5. patient undergoing ECMO
  6. pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
60 participants (estimated)
Target follow-up
28 Days
Patient registry
Yes

Groups and cohorts

  • mechanically ventilated patients with ARDS

    Other: RCexp

Interventions

  • OtherRCexp

    patients received different RCexp

06

What researchers measure

Primary outcomes

  1. Difference in ventilation/perfusion mismatch

    ventilation/perfusion mismatch is measured by EIT

    Time frame: 4 hours

Secondary outcomes

  1. Difference in dead space

    dead space is measured by EIT

    Time frame: 4 hours

  2. Difference in shunt

    shunt is measured by EIT

    Time frame: 4 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2025; primary completion for Dec 2026, 13 months later.

Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 13 months is below that.

Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2025
First posted
Apr 9, 2025
StartEst.
Nov 30, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06919484
Responsible party
Ling Liu (PhD, Southeast University, China) — Principal investigator
First posted
Apr 9, 2025
Start date
Nov 30, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 26, 2025

Study contacts

yuan xue yan, MD
Contact
18826401594@163.com
+86-15901599659

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion